1 citations
,
October 1987 in “Drug Information Journal”
The article concludes that products can affect the body without being drugs as long as they don't claim to treat or prevent diseases, except for cosmetic sunscreens.
2 citations
,
January 2019 in “Applied clinical research, clinical trials and regulatory affairs”
This review discusses the regulations and clinical safety aspects of hair care cosmetics, highlighting the FDA's recommendation to evaluate these products for allergic reactions, avoid contamination, and include antimicrobial agents to ensure consumer safety, with ongoing monitoring through consumer feedback.
15 citations
,
October 2017 in “Journal of Cosmetic and Laser Therapy”
This review identifies FDA-cleared home-use photobiomodulation devices for androgenetic alopecia treatment and highlights their excellent safety profile but notes the lack of long-term comparative studies.
Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
Finasteride is seen as risky for men due to side effects like erectile dysfunction, while hormonal birth control for women is normalized despite its side effects. The discussion points out a double standard influenced by societal and gender norms.
Federal funding for medical research in the U.S. has been halted, potentially delaying new treatments. Hair loss treatments like finasteride and minoxidil are unlikely to be impacted as they are typically funded by private companies.